A total of 430 evaluable patients were enrolled in the study between February 2004 and February 2006, a total of 55 locations in the United States and Europe. Imaging studies were performed before the. At subsequent intervals of about 6-12 weeks CTC were at baseline, 1-2, and 3-5 weeks after initiation of therapy, and in which all subsequent imaging studies using the Immunicon Celltrack technique measured. Metastatic colorectal cancer patients remained in the study and provided blood for up to 12 months or until documented evidence of disease progression and / or death. The long-term survival information can be obtained in all patients by medical entrance examinations at regular intervals up to 24 months after the study.. The colorectal cancer study was a prospective, imaging.
– Immunicon Corporation develops and markets proprietary cell – and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management over Immunicon Corporation. Immunicon has platform technologies for selection and analysis of rare cells in the blood, such as circulating tumor cells developed and circulating endothelial cells, which are important in many diseases and biological processes. These forward-lookingnd underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and to applications in other fields of medicine, as have cardiovascular and infectious diseases. – Immunicon Corporation.In addition, he recommended ‘modest’financial incentive to doctors and patients get more out cost effective medical treatment to encourage.
courtesy of to can entire Kaiser Daily Health Policy Report indicate in 2050 , or sign up for email delivery to Emperor Daily Health policy coverage from strongly supported emperors network. A free service from The Henry J. Releases. Kaiser Family Foundation 2005 Advisory Board Company and Kaiser Family Foundation, All rights reserved.